JINTS BIO为JIN-001,即针对卵巢癌抗药性的HSP90抑制剂,提供了有希望的临床预科结果。 J INTS BIO presents promising preclinical results for JIN-001, a HSP90 inhibitor targeting ovarian cancer drug resistance.

JINTS BIO是一家肿瘤药物开发公司,在巴塞罗那的ENA专题讨论会上,向第二代合成HSP90抑制剂JIN-001提供了前景光明的临时临床初步结果。 J INTS BIO, an oncology drug development firm, presented promising interim preclinical findings for JIN-001, a second-generation synthetic HSP90 inhibitor, at the ENA Symposium in Barcelona. 为了针对卵巢癌中的抗药性,JIN-001提高了标准化疗剂,如巴利塔克斯和皮质结扎剂的效力。 Targeting drug resistance in ovarian cancer, JIN-001 enhances the effectiveness of standard chemotherapy agents like paclitaxel and cisplatin. 该公司旨在为卵巢癌和可能的其他癌症,包括血浆瘤,进一步开发JIN-001。 The company aims to further develop JIN-001 for ovarian cancer and potentially other cancers, including glioblastoma.